DOCSLIB.ORG

Opioid Managementtm a Medical Journal for Proper and Adequate Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioid Managementtm a Medical Journal for Proper and Adequate Use J O U R N A L O F O Journal of OPIOID CERTIFICATION PROGRAM P I O I TM D Presented by M This 2-day program, led by a renowned group of specialists, is designed A N to inform and certify primary care physicians, pain specialists, and A Opioid Management other opioid prescribers in the uses, abuses, and legal ramifications G E of opioids. Upon completion of this program, the Society will issue M E A medical journal for proper and adequate use a framed certif icate verifying completion of the course. Attendance N required at all sessions to receive certificate. T Volume 1, Number 5 NOVEMBER/DECEMBER 2005 ISSN 1551-7489 DAY 1 O n Lega l–Take back your practice n Understanding opioids – M n How do opioids interact with n What do they do and how? CONTENTS OPIOID n other medications? n Addictions & doctor shoppin g– MANAGEMENT n How to handle cancer and why n How to spot a doctor shopper S n OPIOID NEWS AND EVENTS Monitoring outcomes during long-term opioid n Physician side of the legal issue n Pai n– How to deal with it SOCIETY n FBI, DEA, who, why, where, how n Nonopioid ways to deal with pain News briefs . 234 therapy for noncancer pain: Results with the Pain Assessment and Documentation Tool . 257 DAY 2 Calendar . 236 Steven D. Passik, PhD In association with n Tapering someone off opioids n Dosages and under prescribing Kenneth L. Kirsh, PhD n Hazards of long-term opioid use n Opioids for medical traumas n GUEST EDITORIAL Journal of Laurie Whitcomb, MA n Arthritis and Cox2 inhibitors n and diseases What can we learn from baseball’s TM Jeffrey R. Schein, PhD, MPH n out of the picture n Types of opioids and uses steroid scandal? . 237 Opioid Management Mitchell A. Kaplan, PhD n Rotation of opioids n Dosing levels by type of pain Gary M. Reisfield, MD n History and science of opioids n Opioids for neuropathic pain Sheri L. Dodd, MSc George R. Wilson, MD Leah Kleinman, PhD Nathaniel P. Katz, MD n CASE REPORT Russell K. Portenoy, MD DATE SPONSOR AND Dextropropoxyphene and the cardiovascular N April 22 –23, 2006 CERTIFICATE O system: About two cases of acute poisoning Electronically monitored single-use V PROVIDER E patient-controlled analgesia pumps M with cardiac conduction abnormalities . 240 B in postoperative pain control . 267 E Frédérik Staikowsky, MD, PhD Opioid Management Society R / Michael Zimmermann, MD TIME D Sébastien Candella, MD and Journal of Opioid Management E Karin Friedrich, MD C Maurice Raphael, MD Saturday, April 22 – 8 AM TO 4:30 PM 470 Boston Post Road E M Rolf Kirchner, MD Sunday, April 23 – 8 AM TO 3:30 PM B Weston, Massachusetts 02493 E R n PHARMACY PERSPECTIVE 781-899-2702 • fax 781-899-4900 2 0 n LITERATURE REVIEW 0 Methadone in end-of-life pain management . 244 5 Cholecystokinin antagonists: Can they LOCATION Diane L. Chau, MD M. Nathan Mason, MD augment opioid-derived analgesia? . 273 The Conference Center at Harvard Medical CONFERENCE Gary McCleane, MD LEADER 77 Avenue Louis Pasteur n ORIGINAL ARTICLES Boston, Massachusetts 02115-5899 Robert E. Enck, MD, Professor of Medicine, A comparison of oral and implant naltrexone Assistant Division Chief f or Clinical Activities, Division outcomes at 12 months . 249 of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania Ross Colquhoun, BPsych (Hons) Donald Y-K. Tan, MBBS Samantha Hull, BPsych (Hons) REGISTRATION INFORMATION Fee: $695 per person. Registration before November 30, 2005, fee: $645 per person. Fee for JOM subscribers: $595 per person. JOM subscriber registration before November 30, 2005, fee: $545 per person. V O L . 1 , TO REGISTER CONTACT: N O . 5 or : 1-800-743-7206 x103 x107 2 www.opioidmanagementsociety.org 2 5 - 2 8 0 OPIOID CERTIFICATION PROGRAM Presented by O OPIMOID MANAGEMENT STM SOCIETY In association with AD Journal of Opioid Management TM This 2-day program, held at The Conference Center at Harvard Medical in Boston and led by a renowned group of specialists, is designed to inform and certify primary care physicians, pain specialists, and other opioid prescribers in the uses, abuses, and legal ramifications of opioids. Upon completion of the entire program, the Society will issue a framed certificate verifying that you have completed the program. Please see our ad on the back cover for complete Conference details Jour nal of Opioid Management TM A medical journal for proper and adequate use 470 Boston Post Road, Weston, MA 02493 • 781-899-2702 • Fax: 781-899-4900 E-mail: [email protected] • Web site: www.opioidmanagement.com Call for manuscripts Editorial Policy the exception of forum articles, book advise contributors of the status of their sub - The mission of the Journal of Opioid reviews, or letters to the editor, manuscripts missions within 60 days. Management is to educate and promote, should include the following five sections: through scientifically rigorous research, the Abstract, Introduction, Methods, Results, References adequate and safe use of opioids in the and Discus sion. Subheads should be insert - References are organized in AMA for - treatment of pain as well as the legal and ed at suitable levels. Style should conform mat; that is, they are to be cited numerically regulatory issues surrounding abuse, addic - to “Uniform Requirements for Manuscripts in the text and in consecutive order, includ - tion, and prescription practices (both over- Submitted to Biomedical Journals” (avail - ing the first three authors followed by et al., and under-prescribing). Original articles, able online at http://www.icmje.org). and listed at the end of the article in the fol - case studies, literature reviews, editorials, lowing format: and letters to the editor concerning all Figures & Tables Journal articles — aspects of opioid management will be con - The Journal welcomes illustrations, 1. Mudd P, Smith JG, Allen AZ, et al.: sidered for publication. All submissions, charts, and photographs to accompany arti - High ideals and hard cases: The evolution of excluding editorials and letters to the edi - cles. Figures should be titled and numbered opioid therapy for cancer pain. Hastings tor, are subject to peer review by the edito - consecutively according to the citation in Cent Rep . 1982; 12(2):11-14. rial board prior to acceptance. the text. Information presented in figures Books — and tables should be explained in the text. 1. Bayles SP (ed.): Nutritional Supple - Manuscript Submission If data have been published previously, an ments and Interactions with Analgesics . Electronic manuscript submission is pre - appropriate reference should be included. Boston: GK Hall & Co., 1978. ferred. Attach articles in MS Word, Short, descriptive legends should be Book chapters — WordPerfect, or rich text (.rtf) format to the provided on a separate page. Legends for 1. Martin RJ, Post SG: Introducing alterna - journal email address at [email protected]. If figures previously published should include tive prescribing strategies. In Smith J, Howard submitting via regular mail, please supply a complete reference to the original publi - RP, and Donaldson P (eds.): The Oncology your article on a 3-1/2 inch IBM-PC format cation, with the copyright designation. Management Handbook . Madison, WI: floppy disk or CD in MS Word 6.0 or greater, Copies of the publisher's and author's per - Clearwater Press, 1998, pp. 310-334. WordPerfect, or rich text format (.rtf). mission to use the figure must be provided. Web sites — Manuscripts and all correspondence should Photo graphs should include legends and Health Care Financing Administration: be addressed to the Managing Editor, Journal should be numbered consecutively accord - HCFA Statistics at a glance. Available at: of Opioid Management, 470 Boston Post ing to the citation in the text and labeled on www.hcfa/gov/stats/stahili.htm. Accessed Road, Weston, MA 02493. Submit one paper the back. Tables, photos, and figures must December 27, 2002. copy of the manuscript, typed and double- be submitted in the following formats: spaced, with the floppy disk or CD. As a gen - TIFF, JPEG, or EPS. Ethics eral guideline, text should be 1,500 to 2,500 Style should conform to “Uniform Require - words (seven to 12 pages for a research paper, Manuscript review ments for Manuscripts Submitted to Biomedi - three to five manuscript pages for editorials or Manuscripts are received with the under - cal Journals” prepared by the International book reviews). standing that they are submitted solely to Committee of Medical Journal Editors and Journal of Opioid Management and that, pub lished in Ann Intern Med 1997; 126: 36-47, Manuscript Format apart from abstracts, none of the material con - and available on the web at http:www.acpon - The cover page should indicate the arti cle’s tained in the manuscript has been published line.org/journals/annals/01jan97/unifreqr.htm. title, the full name, highest pertinent acade - previously or is under consideration for pub - The Journal expects authors to disclose mic degrees, institutional affiliations, and lication elsewhere. Authors should secure all any commercial or financial associations current address of each author, contact necessary clearances and approvals prior to that might pose a conflict of interest in con - information for the author handling all cor - submission. nection with the submitted article. All fund - respondence, telephone number, fax num - Journal of Opioid Management is a ref - ing sources supporting the work should be ber, and, if the manuscript was orally pre - ereed journal. All manuscripts are generally acknowledged on the title page. sented at a meeting, the name of the organi - subject to review by at least two members of Manuscripts and all correspondence re - zation, place, and date it was read. The first the editorial advisory board who are noted garding them should be addressed to the use of an un common abbreviation should experts in the appropriate subject area.
Load more

Recommended publications
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • Methadone Hydrochloride Tablets, USP) 5 Mg, 10 Mg Rx Only
    ROXANE LABORATORIES, INC. Columbus, OH 43216 DOLOPHINE® HYDROCHLORIDE CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg Rx Only Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. It is critical to understand the pharmacokinetics of methadone when converting patients from other opioids (see DOSAGE AND ADMINISTRATION). Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. Respiratory depression is the chief hazard associated with methadone hydrochloride administration. Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects, particularly in the early dosing period. These characteristics can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. In addition, cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Methadone treatment for analgesic therapy in patients with acute or chronic pain should only be initiated if the potential analgesic or palliative care benefit of treatment with methadone is considered and outweighs the risks. Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid Addiction Code of Federal Regulations, Title 42, Sec 8 Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority.
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Opioid Analgesics These Are General Guidelines
    Adult Opioid Reference Guide June 2012 Opioid Analgesics These are general guidelines. Patient care requires individualization based on patient needs and responses. Lower doses should be used initially, then titrated up to achieve pain relief, especially if the patient has not been taking opioids for the past week (opioid naïve). Patients who have been taking scheduled opioids for at least the previous 5 days may be considered “opioid tolerant”. These patients may require higher doses for analgesia. Drug # Route Starting Dose Onset Peak Duration Metabolism Half Life Comments (Adults > 50 Kg) Buprenorphine Trans- 5 mcg/hr q 7 DAYS 17 hr 60 hr 7 DAYS Liver 26 hr Maximum dose = 20 mcg/hr patch dermal Extensively metabolized by CYP3A4 enzymes – watch for Example: Butrans® drug interactions Transdermal patches are not available at UIHC Codeine PO 30 - 60 mg q 4 hr 30 min 1½ hr 6 hr Liver 2 - 4 hr Oral not recommended first-line therapy. Some patients cannot metabolize codeine to active morphine. Fentanyl IM 5 mcg/Kg q 1 - 2 hr 7 - 8 min 20 - 50 min 1 - 2 hr Liver 1 - 6 hr* Give IV slowly over several minutes to prevent chest wall IV 0.25 - 1 mcg/Kg as Immediate 1 - 5 min 30 - 60 min rigidity SQ needed Refer to the formulary for administration and monitoring. May be used in patients with renal impairment as it has no active metabolites. Accumulates in adipose tissue with continuous infusion. Trans- 25 mcg/hr 12 - 24 hr 24 hr 48 - 72 hr Transdermal should NOT be used to treat acute pain.
    [Show full text]
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • Pain Management After Elective Shoulder Surgery: a Randomized Quantitative Study Comparing Hydromorphone with Piritramide
    Case Report J Anest & Inten Care Med Volume 9 Issue 4 - October 2019 Copyright © All rights are reserved by Hermann Prossinger DOI: 10.19080/JAICM.2019.09.555768 Pain Management After Elective Shoulder Surgery: A Randomized Quantitative Study Comparing Hydromorphone With Piritramide Boesmueller S1, Gerstorfer I1, Steiner M1, Prossinger H2*, Fialka C1 and Steltzer H1, 3 1AUVA Meidling, Austria 2Department for Evolutionary Anthropology, University of Vienna, Austria 3Sigmund Freud University, Austria Submission: September 25, 2019; Published: October 11, 2019 *Corresponding author: Hermann Prossinger, Department for Evolutionary Anthropology, Faculty of Life Sciences, University of Vienna, Vienna, Austria Abstract Background: Postoperative pain management plays an important role in elective shoulder surgery. Several methods have been investigated so far. The aim of this randomized quantitative study is to compare two frequently used postoperative pain regimes (hydromorphone versus piritramide) regarding onset and duration after the effectiveness of the single-shot interscalene block has diminished. Methods: All patients who underwent elective shoulder surgery at our institution agreed to participate in this study. Upon admission patients were assigned membership to group A (hydromorphone) or group B (piritramide) according to the patient number (which ensured randomization). Pain assessment was performed using the numeric rating scale (NRS). For statistical analyses the techniques of maximum likelihood (ML) estimation were used. Results: Of the 48 patients aged 18–89 years included in this study, 25 were in group A and 23 in group B. Of these 48, 21 in each group registered pain levels above threshold at least once. Shoulder surgery was performed 45 times in an arthroscopic and 3 times in an open technique.
    [Show full text]
  • Radiolabelled Molecules for Brain Imaging with PET and SPECT • Peter Brust Radiolabelled Molecules for Brain Imaging with PET and SPECT
    Radiolabelled Molecules for Brain Imaging with PET and SPECT Radiolabelled • Peter Brust Molecules for Brain Imaging with PET and SPECT Edited by Peter Brust Printed Edition of the Special Issue Published in Molecules www.mdpi.com/journal/molecules Radiolabelled Molecules for Brain Imaging with PET and SPECT Radiolabelled Molecules for Brain Imaging with PET and SPECT Editor Peter Brust MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Peter Brust Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Germany Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Molecules (ISSN 1420-3049) (available at: https://www.mdpi.com/journal/molecules/special issues/PET SPECT). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03936-720-7 (Hbk) ISBN 978-3-03936-721-4 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. vii Preface to ”Radiolabelled Molecules for Brain Imaging with PET and SPECT” ........
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • Evidence Review F: Opioids for Pain Relief After Caesarean Birth
    National Institute for Health and Care Excellence FINAL Caesarean birth [F] Opioids for pain relief after caesarean birth NICE guideline NG192 Evidence review March 2021 Final This evidence review was developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products
    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
    [Show full text]
  • ID-75-77 If the United States Is to Develop an Effective International
    UN1TED STATES REPO@F !FfyT’?f?8T CONGRESSOfb7J+ JUL 3 I ?wl llillllllllllillll1lll1lll~llll~~l LM096967 “-...-. x-- If The Un’ited States Is To Develop An Effective International Narcotics Control Program, Much More Must Be Done In this Feport GAO examines U.S. diplomatic actions and other activities aimed at halting International production and trafficking of illicit narcotics and at stopping their flow into the United States. BY THE COMPTROLLER GENERAL OF THE UNITED STATES @ ID-75-77 COMPTROLLER GENERAL OF THE UNITED STATES WASHINGTON. D.C. X’S48 E-175425 To the President of the Senate and the br Speaker of the House of Representatives This report examines U.S. international narcotics control efforts and discusses improvements needed in opera- tions, activities, and related policies and objectives. We made our review pursuant to the Budget and Accounting Act, 1921 (31 U.S.C. 53), and the Accounting and Auditing Act of 1950 (31 U.S.C. 67). We are sending copies of this report to the Director, Office of Management and Budget; the Secretary of State; the Attorney General; and the Administrator, Agency for Inter- national Development. Comptroller General of the United States r- t Contents Page DIGEST i CHAPTER 1 INTRODUCTION AND BACKGROUND General overview Funding Cabinet Committee Scope of review 2 U.S. OPIUM POLICY 8 U.S. opium policy unclear 8 Evolution of an alleged opium shortage 10 Increasing medicinal opiate supplies 13 Agency comments and our evaluation 18 Conclusions 22 Recommendation 22 3 ILLICIT NARCOTICS PRODUCTION AND TRAFFICKING
    [Show full text]